



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Robatumumab

Cat. No.:	HY-P99218
CAS No.:	934235-44-6
Target:	IGF-1R
Pathway:	Protein Tyrosine Kinase/RTK
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Robatumumab (Sch 717454) is an anti-human IGF-1R (insulin-like growth factor receptor-1) antibody. Robatumumab shows anti-tumor activity and anti-proliferative activity to cancer cells. Robatumumab can be used in osteosarcoma and Ewing sarcoma research ^{[1][2]} .								
In Vitro	<p>Robatumumab (0.02-80 nM; 0.5 or 4 h) downregulates IGF-IR and inhibits both basal and IGF-I-induced phosphorylation of IGF-IR and IRS-1 in SK-N-FI cells^[2].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Western Blot Analysis^[2]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>SK-N-FI cells</td> </tr> <tr> <td>Concentration:</td> <td>0.02-80 nM</td> </tr> <tr> <td>Incubation Time:</td> <td>0.5 or 4 hours</td> </tr> <tr> <td>Result:</td> <td>Inhibited the IGF-I-stimulated phosphorylation of IGF-IR after treatment 0.5 h. Resulted in both inhibition of IGF-IR phosphorylation and receptor downregulation after treatment 4 h. Resulted in a dose-dependent inhibition of the IGF-I-stimulated IRS-1 phosphorylation.</td> </tr> </table>	Cell Line:	SK-N-FI cells	Concentration:	0.02-80 nM	Incubation Time:	0.5 or 4 hours	Result:	Inhibited the IGF-I-stimulated phosphorylation of IGF-IR after treatment 0.5 h. Resulted in both inhibition of IGF-IR phosphorylation and receptor downregulation after treatment 4 h. Resulted in a dose-dependent inhibition of the IGF-I-stimulated IRS-1 phosphorylation.
Cell Line:	SK-N-FI cells								
Concentration:	0.02-80 nM								
Incubation Time:	0.5 or 4 hours								
Result:	Inhibited the IGF-I-stimulated phosphorylation of IGF-IR after treatment 0.5 h. Resulted in both inhibition of IGF-IR phosphorylation and receptor downregulation after treatment 4 h. Resulted in a dose-dependent inhibition of the IGF-I-stimulated IRS-1 phosphorylation.								
In Vivo	<p>Robatumumab (intravenous injection; 0.04 or 0.1 mg/mouse; twice weekly; 18 d) inhibits the SK-N-FI tumor growth in xenograft model^[2].</p> <p>Robatumumab (intravenous injection; 0.02-0.5 mg/mouse; twice weekly; 35 d) inhibits the osteosarcoma growth in xenograft model^[2].</p> <p>Robatumumab (intravenous injection; 0.1 or 0.5 mg/mouse; twice weekly; 14 d) inhibits the SJCRH30 and RD rhabdomyosarcoma cell growth in xenograft model^[2].</p> <p>Robatumumab (intravenous injection; 0.1 or 0.5 mg/mouse; twice weekly; 2 w) blocks effectively pediatric tumor cell proliferation in vivo^[2].</p> <p>Robatumumab (intravenous injection; 0.5 mg/mouse; once; day 11 post-inoculation) modulates the blood vessel formation via its antiangiogenesis effect^[2].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>								

Animal Model:	Nude mice inoculated with SK-N-FI tumor cells ^[2]
Dosage:	0.04 or 0.1 mg/mouse
Administration:	Intravenous injection; 0.04 or 0.1 mg/mouse; twice weekly; 18 days
Result:	Inhibited the SK-N-FI xenograft tumor by 96% in the 0.04 mg dose group and resulted in 11% tumor regression in the 0.1 mg dose group.
Animal Model:	Nude mice inoculated with SJSA-1 osteosarcoma ^[2]
Dosage:	0.02, 0.1 or 0.5 mg/mouse
Administration:	Intravenous injection; 0.02, 0.1 or 0.5 mg/mouse; twice weekly; 35 days
Result:	Inhibited the tumor growth by 71%, 82%, and 88% at 0.02, 0.1, and 0.5 mg, respectively, at day 14 after treatment.
Animal Model:	Nude mice inoculated with SJCRH30 and RD rhabdomyosarcoma cells ^[2]
Dosage:	0.1 or 0.5 mg/mouse
Administration:	Intravenous injection; 0.1 or 0.5 mg/mouse; twice weekly; 14 days
Result:	Inhibited tumor growth by 39% and 58% at 0.1 and 0.5 mg dose, respectively, in the RD rhabdomyosarcoma model. Inhibited tumor growth by 37% and 53% at 0.1 and 1 mg dose, respectively, in the SJCRH30 model.
Animal Model:	Nude mice inoculated with SK-N-FI neuroblastoma and SJSA-1 osteosarcoma ^[2]
Dosage:	0.1 or 0.5 mg/mouse
Administration:	Intravenous injection; 0.1 or 0.5 mg/mouse; twice weekly; 2 weeks
Result:	Reduced the tumor Ki-67 staining by 38% and along with significant change in SK-N-FI neuroblastoma xenograft. Reduced the staining of Ki-67 by 37% and 51% after 0.1 and 0.5 mg SCH 717454 treatment, respectively, in the SJSA-1 osteosarcoma xenograft.
Animal Model:	Nude mice inoculated with SJSA-1 osteosarcoma ^[2]
Dosage:	0.5 mg/mouse
Administration:	Intravenous injection; 0.5 mg/mouse; once; day 11 post-inoculation
Result:	Reduced in the intensity of the fluorescent lectin staining by 74% at 0.5 mg dose, showing thinner blood vessels and reduced branches, compared with control IgG1.

REFERENCES

[1]. Anderson PM, et al. A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma. *Pediatr Blood*

Cancer. 2016 Oct;63(10):1761-70.

[2]. Wang Y, et al. A fully human insulin-like growth factor-I receptor antibody SCH 717454 (Robatumumab) has antitumor activity as a single agent and in combination with cytotoxics in pediatric tumor xenografts. Mol Cancer Ther. 2010 Feb;9(2):410-8.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA